4 FDA approvals this Q (Mcap 96 Mil) Hot Pick 2011

[Biotechmaster]

With a market value of $96 million, Anika Therapeutics (ANIK) is a hidden growth story in the biotech arena .ANIK has been profitable for each of the past seven years.

2011 Price Target: $25.00+ .Get in now before the stock gets Discovered .Buy with both hands now and you will make a lot of money with the upcoming FDA approvals .Anika is a once in a lifetime opportunity .GLTA


Anika Therapeutics (ANIK)

Market-Cap: 96 Mil
Cash: 26 Mil
Price: 7.20

Shares Out: 13.5


UPCOMING MILESTONES :

Monovisc (osteoarthritis) (PMA) FDA approval in 1Q 2011 << Blockbuster Potential

Hyaloglide 510(K) expected FDA approval 1Q 2011

Hyalonect 510(K) expected FDA approval 1Q 2011

Hyalofast 510(K) expected FDA approval 1Q 2011



Big Pipeline



Insider Ownership





FAB has commercialized three joint health products that Anika is planning to market in the United States along with MONOVISC

[Biotechmaster]

The Institutions increased their stake in Anika from 30% to 51% in the last few days .VERY POSITIVE SIGN





Shares Outstanding: 13.4 M

Insiders/Mutual/Institutions holding : 8.4 M

Float : 5 M (excluding retail investors)